SCHEMBL4240089

SCHEMBL4240089

Cc1ccc2c(=O)n(NCc3ccc(F)cc3F)c(-c3ccccc3F)nc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.56
MDM2 Q00987 1/20 0.56
NPSR1 Q6W5P4 3/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 2/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
NTRK1 P04629 3/20 0.43
NTRK3 Q16288 2/20 0.43
NTRK2 Q16620 2/20 0.43
GRM2 Q14416 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
CASR P41180 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238065 0.90 ALDH1A1 (0.65) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2
SCHEMBL4245933 0.87 ALDH1A1 (0.51) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2
SCHEMBL4236257 0.83 ALDH1A1 (0.70) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2
SCHEMBL4238037 0.82 ALDH1A1 (0.52) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2
SCHEMBL4237530 0.78 SMN1; SMN2 (0.73) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2
SCHEMBL4241360 0.77 ALDH1A1 (0.62) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2
SCHEMBL4237239 0.76 SMN1; SMN2 (0.61) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2
SCHEMBL4246629 0.75 NPSR1 (0.54) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2
SCHEMBL4236094 0.75 ALDH1A1 (0.62) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2
SCHEMBL4239817 0.72 ALDH1A1 (0.61) ALDH1A1MDM2NPSR1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 ALDH1A1 3192/4885MDM2 4740/4885NPSR1 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.